Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.

Today's Research Daily features the Q4 earnings season scorecard and updated analyst reports on 16 major stocks, including Meta Platforms (META), Mastercard (MA) and Adobe (ADBE), as well as two micro ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Vertex Minerals Ltd (VTX) has commenced commissioning of its recently installed ore sorter at the Hill End gold plant ...

Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and ...

Vertex Bioenergy has secured long-term financing of approximately €350 million. The new platform financing streamlines the ...

Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

While it's next to impossible to know how many opioids entered the state illegally in 2023, we do know that just under 1.7 ...

The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.

The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.